Bruno Beccarini Crescenzi
Overview
Explore the profile of Bruno Beccarini Crescenzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crapanzano C, Casolaro I, Beccarini Crescenzi B, Amendola C
Psychiatr Danub
. 2022 Jun;
34(2):308-309.
PMID: 35772145
No abstract available.
2.
Cuomo A, Beccarini Crescenzi B, Bolognesi S, Goracci A, Koukouna D, Rossi R, et al.
Ann Gen Psychiatry
. 2020 Sep;
19:50.
PMID: 32939220
Background: Major depressive disorder (MDD) is a recurrent illness with high rates of chronicity, treatment-resistance, and significant economic impact. -Adenosylmethionine (SAMe), a molecule that is formed naturally in the human...
3.
Amodeo G, Laurenzi P, Santucci A, Cuomo A, Bolognesi S, Goracci A, et al.
Expert Opin Pharmacother
. 2020 Jun;
21(14):1685-1698.
PMID: 32584616
: Postpartum depressive disorder (PPD) is a burdensome medical condition. To date, only one treatment (Brexanolone) has undergone registrational trials and is approved in the United States with an indication...
4.
Fagiolini A, Bolognesi S, Goracci A, Beccarini Crescenzi B, Cuomo A
Riv Psichiatr
. 2020 Apr;
54(6):1-6.
PMID: 32310932
Cariprazina {RGH-188; trans-N- [4- [2- [4- (2,3-diclorofenil) piperazin-1-il] etil] cicloesil] -N_, N_-dimetilurea cloridrato} è un antipsicotico atipico di nuova generazione, con un originale profilo farmacodinamico e farmacocinetico. Cariprazina ha due...
5.
Cuomo A, Beccarini Crescenzi B, Goracci A, Bolognesi S, Giordano N, Rossi R, et al.
Expert Opin Drug Saf
. 2019 May;
18(6):455-463.
PMID: 31072228
: Safety and tolerability of medications are key variables to inform treatment choice for patients with bipolar disorder (BD). This review focuses on the overall tolerability and safety profile of...
6.
Cuomo A, Maina G, Bolognesi S, Rosso G, Beccarini Crescenzi B, Zanobini F, et al.
Front Psychiatry
. 2019 Apr;
10:167.
PMID: 31001150
Vitamin D inadequacy or deficiency (VDID) has been reported in a high percentage of otherwise healthy individuals. Factors that may contribute to the high prevalence of VDID in people with...
7.
Cuomo A, Bolognesi S, Goracci A, Ciuoli C, Beccarini Crescenzi B, Maina G, et al.
Front Psychiatry
. 2019 Feb;
9:784.
PMID: 30728788
Liraglutide is a once-daily injectable medication approved for the treatment of obesity. Hereby we report the feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood...
8.
Cuomo A, Maina G, Rosso G, Beccarini Crescenzi B, Bolognesi S, Di Muro A, et al.
Front Pharmacol
. 2018 Oct;
9:1040.
PMID: 30374300
The gastrointestinal system hosts roughly 1,800 distinct phyla and about 40,000 bacterial classes, which are known as microbiota, and which are able to influence the brain. For instance, microbiota can...
9.
Cuomo A, Maina G, Neal S, De Montis G, Rosso G, Scheggi S, et al.
Expert Opin Drug Saf
. 2018 Jun;
17(7):719-725.
PMID: 29927667
Introduction: The World Health Organization recommends newborns to be breastfed but this may be challenging if the mother needs to be treated for depression, since strong evidence to inform treatment...